Related references
Note: Only part of the references are listed.Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J. Luke et al.
LANCET (2022)
MEDICC2: whole-genome doubling aware copy-number phylogenies for cancer evolution
Tom L. Kaufmann et al.
GENOME BIOLOGY (2022)
Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience
P. Berlanga et al.
EUROPEAN JOURNAL OF CANCER (2021)
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich et al.
NATURE (2021)
Inherent mosaicism and extensive mutation of human placentas
Tim H. H. Coorens et al.
NATURE (2021)
Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions
Karin Schmelz et al.
NATURE COMMUNICATIONS (2021)
Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer
Emre Kocakavuk et al.
NATURE GENETICS (2021)
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study
Birgit Geoerger et al.
LANCET ONCOLOGY (2020)
Extensive Clonal Branching Shapes the Evolutionary History of High-Risk Pediatric Cancers
Natalie Andersson et al.
CANCER RESEARCH (2020)
Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients
Loredana Amoroso et al.
GENES CHROMOSOMES & CANCER (2020)
The evolutionary history of 2,658 cancers
Moritz Gerstung et al.
NATURE (2020)
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al.
NATURE (2020)
Patterns of somatic structural variation in human cancer genomes
Yilong Li et al.
NATURE (2020)
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
Isidro Cortes-Ciriano et al.
NATURE GENETICS (2020)
Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma
Richard P. Koche et al.
NATURE GENETICS (2020)
Timing the initiation of multiple myeloma
Even H. Rustad et al.
NATURE COMMUNICATIONS (2020)
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial
Kara L. Davis et al.
LANCET ONCOLOGY (2020)
The mutational constraint spectrum quantified from variation in 141,456 humans
Konrad J. Karczewski et al.
NATURE (2020)
Accelerated single cell seeding in relapsed multiple myeloma
Heather J. Landau et al.
NATURE COMMUNICATIONS (2020)
Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers
Hoon Kim et al.
NATURE GENETICS (2020)
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations
Samuel W. Brady et al.
NATURE COMMUNICATIONS (2020)
Isabl Platform, a digital biobank for processing multimodal patient data
Juan S. Medina-Martinez et al.
BMC BIOINFORMATICS (2020)
Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance
Susanne Fransson et al.
SCIENTIFIC REPORTS (2020)
Alignment and mapping methodology influence transcript abundance estimation
Avi Srivastava et al.
GENOME BIOLOGY (2020)
A Compendium of Mutational Signatures of Environmental Agents
Jill E. Kucab et al.
CELL (2019)
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
Lindsay Angus et al.
NATURE GENETICS (2019)
The mutational footprints of cancer therapies
Oriol Pich et al.
NATURE GENETICS (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
Thomas J. Mitchell et al.
CELL (2018)
Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma
Jun S. Wei et al.
CLINICAL CANCER RESEARCH (2018)
The landscape of genomic alterations across childhood cancers
Susanne N. Groebner et al.
NATURE (2018)
Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer
Jenny Karlsson et al.
NATURE GENETICS (2018)
MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent
Tingting Wang et al.
CELL DEATH & DISEASE (2018)
MutationalPatterns: comprehensive genome-wide analysis of mutational processes
Francis Blokzijl et al.
GENOME MEDICINE (2018)
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Xiaotu Ma et al.
NATURE (2018)
A mechanistic classification of clinical phenotypes in neuroblastoma
Sandra Ackermann et al.
SCIENCE (2018)
Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma
Mathieu Chicard et al.
CLINICAL CANCER RESEARCH (2018)
A recurrent novel MGA-NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcoma
Daniel Diolaiti et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2018)
COSMIC: somatic cancer genetics at high-resolution
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression
Julian P. Layer et al.
ONCOIMMUNOLOGY (2017)
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials
Wendy B. London et al.
CANCER (2017)
ClonEvol: clonal ordering and visualization in cancer sequencing
H. X. Dang et al.
ANNALS OF ONCOLOGY (2017)
xCell: digitally portraying the tissue cellular heterogeneity landscape
Dvir Aran et al.
GENOME BIOLOGY (2017)
Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients
Nadine Van Roy et al.
CLINICAL CANCER RESEARCH (2017)
Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone
M. Reza Abbasi et al.
CLINICAL CANCER RESEARCH (2017)
ClinVar: public archive of interpretations of clinically relevant variants
Melissa J. Landrum et al.
NUCLEIC ACIDS RESEARCH (2016)
Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma
Mathieu Chicard et al.
CLINICAL CANCER RESEARCH (2016)
FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
Ronglai Shen et al.
NUCLEIC ACIDS RESEARCH (2016)
Mutational signatures of ionizing radiation in second malignancies
Sam Behjati et al.
NATURE COMMUNICATIONS (2016)
The Ensembl Variant Effect Predictor
William McLaren et al.
GENOME BIOLOGY (2016)
Telomerase activation by genomic rearrangements in high-risk neuroblastoma
Martin Peifer et al.
NATURE (2015)
The evolutionary history of lethal metastatic prostate cancer
Gunes Gundem et al.
NATURE (2015)
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld et al.
NATURE GENETICS (2015)
Mutational dynamics between primary and relapse neuroblastomas
Alexander Schramm et al.
NATURE GENETICS (2015)
TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors
Linda J. Valentijn et al.
NATURE GENETICS (2015)
A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies
K. Althoff et al.
ONCOGENE (2015)
Emergence of New ALK Mutations at Relapse of Neuroblastoma
Gudrun Schleiermacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recurrent Pre-existing and Acquired DNA Copy Number Alterations, Including Focal TERT Gains, in Neuroblastoma Central Nervous System Metastases
David Cobrinik et al.
GENES CHROMOSOMES & CANCER (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh et al.
NATURE GENETICS (2013)
Deciphering Signatures of Mutational Processes Operative in Human Cancer
Ludmil B. Alexandrov et al.
CELL REPORTS (2013)
The Life History of 21 Breast Cancers
Serena Nik-Zainal et al.
CELL (2012)
Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
Nai-Kong V. Cheung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
Jane Carr-Wilkinson et al.
CLINICAL CANCER RESEARCH (2010)
Medical Progress: Recent Advances in Neuroblastoma.
John M. Maris
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Tom Monclair et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sprouty2 regulates growth and differentiation of human neuroblastoma cells through RET tyrosine kinase
Maki Ishida et al.
CANCER SCIENCE (2007)
Share Paper
